Simultaneous Inhibition of Estrogen Receptor and the HER2 Pathway in Breast Cancer: Effects of HER2 Abundance
about
Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance.Tyrosine dephosphorylation enhances the therapeutic target activity of epidermal growth factor receptor (EGFR) by disrupting its interaction with estrogen receptor (ER).3D culture of Her2+ breast cancer cells promotes AKT to MAPK switching and a loss of therapeutic response.Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance.Fulvestrant regulates epidermal growth factor (EGF) family ligands to activate EGF receptor (EGFR) signaling in breast cancer cells.Modelling the effect of GRP78 on anti-oestrogen sensitivity and resistance in breast cancer.Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial.Inhibition of RET increases the efficacy of antiestrogen and is a novel treatment strategy for luminal breast cancer.Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.Eugenol alleviated breast precancerous lesions through HER2/PI3K-AKT pathway-induced cell apoptosis and S-phase arrest.Preparation and preclinical evaluation of 131 I-trastuzumab for breast cancer.A combination of p53-activating APR-246 and phosphatidylserine-targeting antibody potently inhibits tumor development in hormone-dependent mutant p53-expressing breast cancer xenografts.Activating HER3 mutations in breast cancer.Development of a Nanostructured Platform for Identifying HER2-Heterogeneity of Breast Cancer Cells by Surface-Enhanced Raman Scattering
P2860
Q33648503-8A472165-06C0-435C-98D6-F9368BBB7D9CQ35955297-26D322E1-DA43-44ED-8CB0-D8A6C9689B02Q36037262-EA726DBF-085B-44BD-AFA7-0AD1F8D032ADQ36589865-B9CA56BA-94FF-42CE-9DB7-25EC6EC974ECQ37013935-C12647DF-AE03-426D-856C-E8E1C95E868BQ37561430-BC22470C-4954-4904-98D2-F484C5B228E0Q37632118-C21ED1A1-28DD-4A90-99BB-20CBFFB39B71Q37707145-0ED7D6B5-5590-4884-AFD6-96D6C83A6705Q38818614-B114ACBA-E9DA-4297-A8F1-AAB6AAD102B0Q41346977-8A6C968A-5164-4F13-AD7D-5858EDCDD56BQ51076764-EA173386-C6F8-4DD3-8B97-1014BB2AE630Q52722381-BEFFA5FE-3C0B-4837-8FED-017EA6F08936Q55379622-3E9677C8-37A9-4352-823E-32FA80974CF6Q57139047-3F96515E-280C-49A9-9D42-08BB0C5069BE
P2860
Simultaneous Inhibition of Estrogen Receptor and the HER2 Pathway in Breast Cancer: Effects of HER2 Abundance
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Simultaneous Inhibition of Est ...... cer: Effects of HER2 Abundance
@ast
Simultaneous Inhibition of Est ...... cer: Effects of HER2 Abundance
@en
type
label
Simultaneous Inhibition of Est ...... cer: Effects of HER2 Abundance
@ast
Simultaneous Inhibition of Est ...... cer: Effects of HER2 Abundance
@en
prefLabel
Simultaneous Inhibition of Est ...... cer: Effects of HER2 Abundance
@ast
Simultaneous Inhibition of Est ...... cer: Effects of HER2 Abundance
@en
P2093
P2860
P356
P1476
Simultaneous Inhibition of Est ...... cer: Effects of HER2 Abundance
@en
P2093
Benjamin Ribba
Georg Mahlknecht
Kerstin Maslak
Kurt Possinger
Michael Sela
Yosef Yarden
P2860
P304
P356
10.1593/TLO.11127
P577
2011-10-01T00:00:00Z